Serum and synovial fluid levels of interleukin-17a in primary knee osteoarthritis patients: Correlations with functional status, pain, and disease severity

Shereen Kamel, Rehab Khalaf, Hend Moness, Shimaa Ahmed

1Department of Rheumatology and Rehabilitation, Faculty of Medicine, Minia University, Minia, Egypt
2Department of Clinical Pathology, Faculty of Medicine, Minia University, Minia, Egypt

ABSTRACT

Objectives: This study aims to assess the serum and synovial fluid (SF) levels of interleukin (IL)-17A in primary knee osteoarthritis (KOA) patients and to study their correlations with functional status, pain, and disease severity.

Patients and methods: This cross-sectional study was conducted between December 2017 and March 2018 and it included 70 patients (46 males, 24 females; mean age 57.3±10.0 years; range 34 to 76 years) with primary KOA and 30 age-, sex-, and body mass index-matched healthy individuals (20 males, 10 females; mean age 53.3±10.3 years; range, 35 to 70 years). Western Ontario and McMaster Universities osteoarthritis index (WOMAC), visual analog scale (VAS), Lequesne index, and Kellgren and Lawrence (KL) grading scale were used for assessment of the disease. IL-17A levels were measured in the serum for patients and healthy controls, and in SF for patients only using an enzyme-linked immunosorbent assay.

Results: Serum levels of IL-17A were significantly higher in KOA patients than controls (p=0.04). A positive correlation was found between serum and SF IL-17A levels. Serum and SF IL-17A levels had positive correlations with VAS, WOMAC pain score, Lequesne pain score, WOMAC function score, and Lequesne index. SF IL-17A levels had strong positive correlations with radiographic severity (KL grade) and duration of OA.

Conclusion: Higher IL-17A levels in primary KOA patients were significantly associated with longer disease duration, higher pain scores, worse quality of life, extreme disability, and advanced structural damage. Therapeutics that target IL-17A warrant further investigation.

Keywords: Interleukin-17, knee, osteoarthritis, serum, synovial fluid.

Osteoarthritis (OA) is the most common form of arthritis causing pain and disability. It is characterized by loss of articular cartilage and formation of osteophytes with synovial inflammation present in a significant proportion of patients. Primary OA most frequently affects the hips and the knees.

Proinflammatory cytokines (interleukin-1 beta [IL-1β], tumor necrosis factor-alpha [TNF-α], IL-6, IL-15, IL-18 and IL-17) have been shown to play important roles in the destruction of cartilage, synovitis, and pain. IL-17 is the original member of a new group of cytokines (IL-17 A-F), produced mainly by IL-17-secreting CD4+ cells (also known as T helper 17 [Th17] cells). The most frequently investigated members of IL-17 family were two proteins: IL-17A and IL-17F. In rheumatoid arthritis (RA), IL-17A and IL-17F affected the synoviocytes by stimulating similar yet different signaling pathways. Also, IL-17A regulated a larger number of genes associated with inflammatory processes than IL-17F. Increased expression of...
IL-17A was not restricted to synovial tissues of RA patients, as it was also observed in other forms of arthritis, including primary OA.\textsuperscript{7}

Interleukin-17 can promote cartilage, synovial cells, macrophages, and osteocytes to produce the inflammatory cytokines such as TNF-\(\alpha\), IL-1\(\beta\), and IL-6. IL-17 cells can promote receptor activator of nuclear factor-kappa B ligand (RANKL) differentiation in osteoblasts, and stimulate the degradation of matrix metallopeptidases and extracellular matrix, and the activity of bone resorption. In addition, IL-17 can also stimulate many chemokines; these chemokines can cause aggregation of neutrophils, macrophages, and lymphocytes in the synovial membrane, which creates a cascade amplification effect, resulting in more severe joint damage.\textsuperscript{8}

Multiple studies have confirmed that IL-17 is the main factor leading to OA bone injury.\textsuperscript{7,9,10} Clinical data also indicate that the levels of IL-17 and IL-17R are higher in the synovial fluid (SF) of patients with arthritis.\textsuperscript{10} However, the impact of elevated IL-17 levels on OA severity and/or disability is still poorly investigated. Thus, in this study, we aimed to assess the serum and SF levels of IL-17A in primary knee OA (KOA) patients and to study their correlations with functional status, pain, and disease severity.

**PATIENTS AND METHODS**

The present cross-sectional study was conducted at Department of Rheumatology and Rehabilitation, Minia University Hospital between December 2017 and March 2018. EPi Info software version 2000 (Centers for Disease Control and Prevention, Atlanta, Georgia, USA) was used to determine the sample size considering the target population as 85 patients per month, the prevalence of OA as 40\%\textsuperscript{11} with the confidence level at 95\%, a power of 80\%, alpha=0.05, and beta=0.10. Accordingly, 70 primary KOA patients with knee effusion (46 males, 24 females; mean age 57.3±10.0 years; range, 34 to 76 years) who fulfilled the American College of Rheumatology clinical and radiographic diagnostic criteria for KOA\textsuperscript{12} were included. Thirty healthy age-, sex-, and body mass index (BMI)-matched individuals (20 males, 10 females; mean age 53.3±10.3 years; range, 35 to 70 years) without any sign or symptom suggestive of OA, gout, RA, trauma, diabetes or other orthopedic disease served as the control group.

Patients with secondary OA due to trauma (known history of fracture or previous surgery) or known inflammatory arthritis or autoimmune diseases, patients with history of steroid injections over the past three months or those with neurological conditions or medical comorbidity (e.g., terminal conditions such as end-stage renal disease, associated severe liver dysfunction heart failure or malignancy) were excluded.

For anthropometry, height was measured to the nearest 0.1 cm, weight was measured in the upright position to the nearest 0.1 kg, and BMI was calculated as weight in kilograms divided by the square of height in meters.

For disease assessment, visual analog scale (VAS) was utilized which is a horizontal line, 100 mm in length, anchored by word descriptors at each end. The patient marks on the line the point that represents their perception of their current state. A higher score indicates greater pain intensity.\textsuperscript{13} Moreover, Western Ontario and McMaster Universities osteoarthritis index (WOMAC) was used which is a valid and reliable instrument for the assessment of OA of the lower extremities.\textsuperscript{14} It consists of 24 items divided into three subscales. The pain scale includes five items asking about pain at activity or rest. The stiffness scale includes two questions. The function dimension explores the degree of difficulty in daily activities. The scores are summed for items in each subscale, with possible ranges as follows: pain=0-20, stiffness=0-8, physical function=0-68, and total WOMAC score is created by summing the items for all three subscales (0-96).

Lequesne index was used to evaluate the severity for knee disease. It is a 10-question survey, five questions pertaining to pain or discomfort, one question dealing with maximum distance walked, and four questions about activities of daily living. The total questionnaire is scored on a 0 to 24 scale. Lower scores indicate less functional impairment.\textsuperscript{15}
### Table 1. Demographic and clinical characteristics of studied population

|                      | Healthy controls (n=30) | Knee osteoarthritis patients |
|----------------------|-------------------------|-----------------------------|
|                      | n | Mean±SD | Range | n | Mean±SD | Range | n | Mean±SD | Range | n | Mean±SD | Range |
| Age (year)           | 53.3±10.3 | 35-70 | 57.3±10.0 | 34-76 | 56.5±10.8 | 34-70 | 56.3±9.9 | 35-72 | 62.7±8.2 | 50-76 |
| Sex                  |   | Male | Female |   | Male | Female |   | Male | Female |   | Male | Female |
|                      | 20 | 46 | 14 | 20 | 46 | 14 | 20 | 46 | 14 | 20 | 46 | 14 |
| BMI (kg/m²)          | 27.1±3.1 | 21.6-32.6 | 27.8±3.3 | 21.8-32.9 | 25.2±2.7 | 21.8-29.5 | 28.6±2.3 | 22.1-32.4 | 31.3±1.4 | 29.3-32.9 |
| Disease duration (year) | NA | NA | 1-15 | 1-5 | 3-8 | 1-5 | 3-8 | 1-5 | 3-8 |

KL: Kellgren and Lawrence grading scale; SD: Standard deviation; BMI: Body mass index; NA: Not applicable; No statistically significant differences between groups (p>0.05; analysis of variance test).

### Table 2. Assessment of pain and functional status in knee osteoarthritis patients

|                      | Total (n=70) | KL Grade 2 (n=26) | KL Grade 3 (n=30) | KL Grade 4 (n=14) |
|----------------------|-------------|-------------------|-------------------|-------------------|
|                      | Mean±SD | Range | Mean±SD | Range | Mean±SD | Range | Mean±SD | Range | F | p* |
| VAS pain             | 48.6±21.3 | 20-80 | 26.2±9.6 | 20-40 | 55.3±7.4 | 40-60 | 78.6±3.8 | 70-80 | 24.87 | <0.001 |
| WOMAC pain score     | 11.6±3.4 | 6-19 | 9.2±1.7 | 6-12 | 13.5±1.5 | 11-16 | 16.7±1.5 | 14-19 | 15.63 | <0.001 |
| WOMAC stiffness score | 3.9±2.3 | 0-7 | 1.7±1.8 | 0-5 | 4.5±1.1 | 3-7 | 6.6±0.8 | 5-7 | 21.47 | <0.001 |
| WOMAC functional score | 41.1±11.2 | 20-58 | 28.7±6.1 | 20-42 | 45.6±3.4 | 41-51 | 54.6±3.9 | 47-58 | 19.88 | <0.001 |
| WOMAC overall score  | 57.3±16.5 | 26-82 | 38.8±8.4 | 26-56 | 63.7±3.8 | 59-70 | 77.9±5.1 | 67-82 | 23.67 | <0.001 |
| Lequesne pain score  | 4.3±1.5 | 2-8 | 2.8±0.6 | 2-4 | 4.6±0.6 | 4-6 | 6.7±1.0 | 5-8 | 86.14 | <0.001 |
| Lequesne maximum distance walked score | 2.3±1.1 | 1-6 | 1.3±0.5 | 1-2 | 2.5±0.5 | 2-3 | 3.9±1.1 | 3-6 | 65.19 | <0.001 |
| Lequesne activities of daily living score | 3.8±1.3 | 2-7 | 2.7±0.6 | 2-4 | 3.9±0.6 | 3-5 | 5.7±0.8 | 5-7 | 47.9 | <0.001 |
| Lequesne overall score | 10.4±3.6 | 5-21 | 6.8±1.1 | 5-9 | 11±1.3 | 9-13.5 | 15.9±2.3 | 14-21 | 121.6 | <0.001 |

KL: Kellgren and Lawrence grading scale; SD: Standard deviation; VAS: Visual analog scale; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index; * Significant p value <0.05 (analysis of variance test for comparison between three groups of patients).
RESULTS

The demographic and clinical characteristics of the studied population are displayed in Table 1. According to KL grading scale, 26 (37.1%) patients had Grade 2, 30 (42.8%) had Grade 3, and 14 (20%) had Grade 4. Sixty-eight patients (97.1%) were using non-steroidal anti-inflammatory drugs and six patients (8.6%) were using chondroprotective drugs. Assessment of pain and functional status in KOA patients are shown in Table 2.

The IL-17A levels were measured in the serum of patients and controls and in the SF of patients only using human IL-17 PicoKine enzyme-linked immunosorbent assay (ELISA) Kit (Boster Biological Technology, Pleasanton CA, USA). SF specimens were collected through knee arthrocentesis. The symptomatic knee was pointed as the index joint. If patients had bilateral KOA, the most symptomatic one was selected for aspiration.

Statistical analysis

Statistical analysis was performed using the SPSS version 16.0 (SPSS Inc., Chicago, IL, USA) software. Descriptive statistics were presented by number and percentage as well as mean and standard deviation. Statistical differences between groups were tested using Chi-square test for qualitative variables, independent sample t-test, and analysis of variance (ANOVA) for quantitative normally distributed variables. When there was a statistically significant difference, post hoc test by Tukey's honest significant difference (HSD) method was used to confirm where the differences occurred between groups. Assessment of normality was analyzed using the Shapiro-Wilk test. Correlations were calculated using Pearson's correlation coefficient. The level of statistical significance was set at p<0.05.

| Parameter               | Healthy controls (n=30) | Osteoarthritis patients | Osteoarthritis patients |
|-------------------------|-------------------------|-------------------------|-------------------------|
|                         | Mean±SD                 | Total (n=70)            | KL Grade 2 (n=26)       | KL Grade 3 (n=30)       | KL Grade 4 (n=14)       |
| Serum IL-17A (pg/mL)    | 10.5±1.9                | 11.6±1.6*               | 10.2±0.7               | 11.8±0.7                | 14.1±1.2*               |
| Synovial fluid IL-17A (pg/mL) | NA                      | 39.2±5.5               | 29.4±3.7               | 41.3±3.1†               | 53.1±4.7†               |

KL: Kellgren and Lawrence grading scale; SD: Standard deviation; IL-17: Interleukin-17; NA: Not applicable.
Serum IL-17 concentrations: * P<0.05 vs. controls.
Synovial fluid IL-17 concentrations: † P<0.05 vs. KL Grade 2; ‡ P<0.05 vs. KL Grade 3;
Student’s t-test or analysis of variance test.

Grading of KOA severity was performed using the Kellgren and Lawrence (KL) grading scale. The radiological severity was categorized into four grades as follows: very mild (Grade 1), mild (Grade 2), moderate (Grade 3), and severe (Grade 4).16

The IL-17A levels were measured in the serum of patients and controls and in the SF of patients only using human IL-17 PicoKine enzyme-linked immunosorbent assay (ELISA) Kit (Boster Biological Technology, Pleasanton CA, USA). SF specimens were collected through knee arthrocentesis. The symptomatic knee was pointed as the index joint. If patients had bilateral KOA, the most symptomatic one was selected for aspiration.
patients with KL Grade 3 and those with KL Grade 4 (p<0.001 for each).

There was a significant weak positive correlation between serum and SF IL-17A levels in OA patients (r=0.34, p=0.04) as shown in Figure 1. The correlations between IL-17A profile and analyzed parameters in OA patients are shown in Table 4.

**DISCUSSION**

In the present study, the serum levels of interleukin-17A were significantly higher in KOA patients than controls, as reported by previous studies.\textsuperscript{4,17-21} Wang and Mu\textsuperscript{22} reported increased serum IL-17A levels in KOA patients while they were not statistically different from those in the controls (1.6±0.0 vs. 1.1±0.0), which may be referred to patients’ selection as they included patients who underwent arthroscopic surgery for advanced KOA. However, they observed that SF and synovial membrane IL-17 levels were significantly higher in patients with KOA compared with controls.

Our results revealed that serum and SF IL-17A levels tended to be higher with the increment of KL grade with statistically significant differences. Serum IL-17A levels were significantly higher in patients with KL Grade 4 than in controls. SF IL-17A levels were significantly higher in patients with KL Grade 4 than in those with KL Grade 3 or KL Grade 2, and significantly higher in patients with KL Grade 3 than those with KL Grade 2. These findings were in agreement with the studies of Chen et al.\textsuperscript{4} and Wan et al.\textsuperscript{20}

The current study showed a significant positive correlation between serum and SF IL-17A levels in primary KOA patients. A similar correlation

| Table 4. Correlations between IL-17A profile and analyzed parameters |
|---------------------------------------------------------------|
|                | Serum IL-17A | Synovial fluid IL-17A |
|                | r   | p    | r   | p    |
| Age of the patients | 0.15 | 0.38 | 0.12 | 0.48 |
| Disease duration | 0.29 | 0.09 | 0.66 | <0.001* |
| Body mass index | 0.24 | 0.15 | 0.51 | 0.002* |
| Visual analog scale | 0.42 | 0.01* | 0.91 | <0.001* |
| WOMAC pain score | 0.37 | 0.02* | 0.87 | <0.001* |
| WOMAC stiffness score | 0.37 | 0.02* | 0.82 | <0.001* |
| WOMAC functional score | 0.35 | 0.03* | 0.90 | <0.001* |
| WOMAC overall score | 0.39 | 0.02* | 0.92 | <0.001* |
| Lequesne pain score | 0.37 | 0.02* | 0.81 | <0.001* |
| Lequesne maximum distance walked score | 0.40 | 0.01* | 0.78 | <0.001* |
| Lequesne activities of daily living score | 0.37 | 0.02* | 0.85 | <0.001* |
| Lequesne index | 0.40 | 0.01* | 0.87 | <0.001* |
| KL grading scale | 0.33 | 0.052 | 0.93 | <0.001* |

IL-17: Interleukin-17; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index; KL: Kellgren and Lawrence grading scale; * Significant p value <0.05.
was reported by Lubbeke et al.\textsuperscript{23} and Snelling et al.\textsuperscript{24} and this correlation proposed capability of IL-17 as a non-invasive biomarker for disease stratification.

To our knowledge, our study is the first reporting a strong positive correlation between SF IL-17A levels and the duration of KOA.

Miller and Malfait\textsuperscript{25} suggested that IL-17 may have a significant role in mechanical pain. Our results support this suggestion, as we found that serum and SF IL-17A levels had significant positive correlations with VAS, WOMAC pain score, and Lequesne pain score, with notable very strong positive correlations of SF IL-17A levels with pain scores. In agreement with our results, Mohamed et al.\textsuperscript{19} and Askari et al.\textsuperscript{18} observed a significant positive correlation between serum IL-17 and WOMAC pain score; and results of Liu et al.\textsuperscript{17} revealed a significant positive correlation between SF IL-17 levels and WOMAC pain score in primary KOA patients. On the contrary, Torres et al.\textsuperscript{26} found that pain had indirect relation to IL-17 as it might be related to other factors occurring in the pathology of OA such as bone attrition.

Our results also revealed that serum IL-17A levels had significantly weak positive correlations with total WOMAC score, WOMAC stiffness score, and WOMAC function score, while SF IL-17A levels had significantly very strong positive correlations with the previous scores. In agreement with our results, several authors.\textsuperscript{14,27-30} have described the association of disability, measured by the WOMAC scores, with higher levels of proinflammatory cytokines.

In the current study, serum and SF IL-17A levels had positive correlations with Lequesne index (an objective assessment of OA severity), Lequesne maximum distance walked score, and Lequesne activities of daily living score.

In agreement with our results, Chen et al.\textsuperscript{4} reported positive correlation between SF IL-17 level and Lequesne index among 98 primary KOA patients; however, they observed no correlation between serum IL-17 concentrations and Lequesne index and suggested that local and systemic production of IL-17 by synovial cells and chondrocytes in local and extra-articular tissues might be leading to increased level of SF IL-17 only. Mohamed et al.\textsuperscript{19} support our results as they reported positive correlation between serum IL-17 and Lequesne index.

In the present study, SF IL-17A level not serum had a very strong positive correlation with severity of KOA (KL grade) which reflects the bone destructive role of IL-17 in OA. In concordance with our results, Wang and Mu\textsuperscript{22} showed that IL-17 levels in the SF and synovial membrane are positively correlated with KOA severity, while they evaluated the severity of knee articular cartilage damage and synovitis-related pathological changes by arthroscopy using the Outerbridge and Ayral scores. In contrast to our results, Liu et al.\textsuperscript{17} reported no correlation between SF IL-17 level and KL grade, which may be referred to the method of patients' selection as they included KOA patients with KL grade ≥1.

In agreement with our study, researchers in a cross-sectional study\textsuperscript{31} reported that serum IL-17 was not associated with KL grade. On the contrary, Mathiessen and Conaghan\textsuperscript{32} and Mohamed et al.\textsuperscript{19} found a positive link between serum IL-17 levels and the severity of KOA using KL grade. The low number of patients in our study with absence of patients with KL Grade 1 may explain the difference with the previous studies.

The present study had some limitations. Firstly, there were statistical limitations mainly in terms of power due to the relatively low number of patients. Secondly, we measured IL-17A levels in serum and SF of KOA patients; however, the detection of IL-17A expression in synovial membrane of KOA patients could have revealed more valuable information on the potential pathophysiological role of IL-17A. Lastly, we could not measure other inflammatory biomarkers (e.g., IL-1, IL-6, and TNF-\alpha) which may provide further valuable information on the role of the IL-17 signaling pathway in OA related-pain and in radiographic progression.

In conclusion, higher IL-17A levels in primary KOA patients were significantly associated with longer disease duration, higher pain scores, worse quality of life, extreme disability, and advanced structural damage. These findings are important because they open a window of possibility for the early use of IL-17 antagonists for the prevention of joint destruction. Further studies with higher
numbers of KOA patients are recommended to classify patients according to IL-17 levels and to verify our results.

Ethics Committee Approval: The study protocol was approved by the Faculty of Medicine Ethics Committee. The study was conducted in accordance with the principles of the Declaration of Helsinki.

Patient Consent for Publication: A written informed consent was obtained from each participant.

Data Sharing Statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Author Contributions: Wrote manuscript: S.K.; Contributes to preparation: R.K.; Measured IL-17 in all patients: H.M.; Performed analytic calculation: S.A.

Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Funding: The authors received no financial support for the research and/or authorship of this article.

REFERENCES

1. Atukorala I, Kwoh CK, Guermazi A, Roemer FW, Boudreau RM, Hannon MJ, et al. Synovitis in knee osteoarthritis: a precursor of disease? Ann Rheum Dis 2016;75:390-5.
2. Coggon D, Reading I, Croft P, McLaren M, Barrett D, Cooper C. Knee osteoarthritis and obesity. Int J Obes Relat Metab Disord 2001;25:622-7.
3. E X, Cao Y, Meng H, Qi Y, Du G, Xu J, et al. Dendritic cells of synovium in experimental model of osteoarthritis of rabbits. Cell Physiol Biochem 2012;30:23-32.
4. Chen B, Deng Y, Tan Y, Qin J, Chen LB. Association between severity of knee osteoarthritis and serum and synovial fluid interleukin 17 concentrations. J Int Med Res 2014;42:138-44.
5. Espinoza JL, Takami A, Nakata K, Onizuka M, Kawase T, Akiyama H, et al. A genetic variant in the IL-17 promoter is functionally associated with acute graft-versus-host disease after unrelated bone marrow transplantation. PLoS One 2011;6:e26229.
6. Hot A, Miossec P. Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes. Ann Rheum Dis 2011;70:727-32.
7. van Baarsen LG, Lebre MC, van der Coelen D, Aarrass S, Tang MW, Ramwadhdoebe TH, et al. Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy? Arthritis Res Ther 2014;16:426.
8. Wojdasiewicz P, Poniatowski ŁA, Szukiewicz D. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators Inflamm 2014:2014:561459.
9. Suurmond J, Dorée AL, Boon MR, Knol EF, Huizinga TW, Toes RE, et al. Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium. Arthritis Res Ther 2011;13:R150.
10. Southam L, Heath O, Chapman K, Loughlin J. Association analysis of the interleukin 17 genes IL17A and IL17F as potential osteoarthritis susceptibility loci. Ann Rheum Dis 2006;65:556-7.
11. Hassan SK. A Study of Morbidity Pattern among Geriatric Population in Fayoum Governorate, Egypt. J Am Sci 2015;11:90-5.
12. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039-49.
13. Huskisson EC. Measurement of pain. Lancet 1974;2:1127-31.
14. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40.
15. Lequesne M, Mery C. European guidelines for clinical trials of new antirheumatic drugs. EULAR Bull 1980;9:171-5.
16. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthritis. Ann Rheum Dis 1957;16:494-502.
17. Liu Y, Peng H, Meng Z, Wei M. Correlation of IL-17 Level in Synovia and Severity of Knee Osteoarthritis. Med Sci Monit 2015;21:1732-6.
18. Askari A, Naghizadeh MM, Homayounfar R, Shahi A, Afsarian MH, Paknahad A, et al. Increased Serum Levels of IL-17A and IL-23 Are Associated with Decreased Vitamin D3 and Increased Pain in Osteoarthritis. PLoS One 2016;11:e0164757.
19. Mohamed SA, Neseem NO, Metwally SS, Farag SM. IL-17 in primary knee osteoarthritis and its relation with severity of the disease. International Journal of Clinical Rheumatology 2018;13:1758-4272.
20. Wan L, Zhao Q, Niu G, Xiang T, Ding C, Wang S. Plasma miR-136 can be used to screen patients with Interleukin-17A in Primary Knee Osteoarthritis Patients
knee osteoarthritis from healthy controls by targeting IL-17. Exp Ther Med 2018;16:3419-24.

21. Jiang L, Zhou X, Xiong Y, Bao J, Xu K, Wu L. Association between interleukin-17A/F single nucleotide polymorphisms and susceptibility to osteoarthritis in a Chinese population. Medicine (Baltimore) 2019;98:e14944.

22. Wang GL, Mu WD. IL-17 expression in synovial fluid and synovial membrane in patients with knee osteoarthritis. Int J Clin Exp Med 2017;10:3400-5.

23. Lubbeke A, Bas S, Puskas GJ, Suva D, Finckh A, Gabay C et al. Presence of interleukin-17 in osteoarthritis: Does it indicate a different osteoarthritis phenotype. Osteoarthritis Cartilage 2015;Suppl 23:A321.

24. Snelling SJ, Bas S, Puskas GJ, Dakin SG, Suva D, Finckh A, et al. Presence of IL-17 in synovial fluid identifies a potential inflammatory osteoarthritic phenotype. PLoS One 2017;12:e0175109.

25. Miller RE, Miller RJ, Malfait AM. Osteoarthritis joint pain: the cytokine connection. Cytokine 2014;70:185-93.

26. Torres L, Dunlop DD, Peterfy C, Guermazi A, Prasad P, Hayes KW, et al. The relationship between specific tissue lesions and pain severity in persons with knee osteoarthritis. Osteoarthritis Cartilage 2006;14:1033-40.

27. Ferraro KF, Booth TL. Age, body mass index, and functional illness. J Gerontol B Psychol Sci Soc Sci 1999;54:S339-48.

28. Ferrucci L, Penninx BW, Volpato S, Harris TB, Bandeen-Roche K, Balfour J, et al. Change in muscle strength explains accelerated decline of physical function in older women with high interleukin-6 serum levels. J Am Geriatr Soc 2002;50:1947-54.

29. Imamura M, Imamura ST, Kaziyama HH, Targino RA, Hsing WT, de Souza LP, et al. Impact of nervous system hyperalgesia on pain, disability, and quality of life in patients with knee osteoarthritis: a controlled analysis. Arthritis Rheum 2008;59:1424-31.

30. Miller GD, Nicklas BJ, Loeser RF. Inflammatory biomarkers and physical function in older, obese adults with knee pain and self-reported osteoarthritis after intensive weight-loss therapy. J Am Geriatr Soc 2008;56:644-51.

31. Wang K, Xu J, Cai J, Zheng S, Han W, Antony B, et al. Serum levels of interleukin-17 and adiponectin are associated with infrapatellar fat pad volume and signal intensity alteration in patients with knee osteoarthritis. Arthritis Res Ther 2016;18:193.

32. Mathiessen A, Conaghan PG. Synovitis in osteoarthritis: current understanding with therapeutic implications. Arthritis Res Ther 2017;19:18.